PharmaLectures.com

Courses › Pharma training by line of business › The regulatory file every European buyer will ask the biologics and biosimilars maker for

The regulatory file every European buyer will ask the biologics and biosimilars maker for

Send buyers a biologics dossier that clears European validation the first time.

  • 8 audio modulesthree lengths each
  • 1 h 20 min to 6 h 40 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Biologics and biosimilarswho it is written for

Why this training matters

Your dossier reaches the European Medicines Agency, and validation comes back with questions about Module 3. The start of the procedure waits while your team hunts for the missing control strategy. Your commercial partner watches the launch date slip and starts talking to someone else.

What changes after this course

Your team files a Common Technical Document that answers the reviewer and the buyer before either asks. Each learner answers a recorded multiple-choice questionnaire after every module. You hold a certificate per learner and a training record per person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory team stops searching for the right guideline. They open the file knowing that Regulation 726/2004 puts your biologic on the centralized procedure, which European Medicines Agency guidelines apply, and what the Rapporteur and Co-Rapporteur read first. The Common Technical Document goes together in the right folders from the start, so validation has little to flag.

A quality assurance specialist reads a Module 3 draft and spots the missing critical quality attribute before the buyer does. The active substance section carries the full process description and the stability evidence. Release methods and limits follow International Council for Harmonisation guideline Q6B, and batch results match the specification you filed, so shipments are not held for a query.

Clinical and non-clinical authors write Modules 2.4 and 2.5 so a partner finds the answer on the first read. Comparability work follows the European biosimilar guidelines, and guideline Q5E for manufacturing changes. The bridging data against a non-European reference product sit where the reviewer looks for them, and the statistics make the case without another study.

After approval, a change request lands and nobody panics. Your staff sorts it into Type IA, Type IB, Type II or extension under Commission Regulation 1234/2008, files it through the electronic Common Technical Document, and keeps the pharmacovigilance system master file current. Before any new submission, a checklist finds the missing validation report first.

Who needs this training

  • Regulatory Affairs Manager

    Builds the dossier and answers the validation letter. After the course, they set up the Common Technical Document folders correctly the first time and match comparability data to the right European guideline.

  • Quality Assurance Specialist

    Checks release specifications against what the dossier says. After the course, they confirm each release method and limit matches Module 3 before an inspector or a buyer compares them.

  • Research and Development Scientist for Biologics

    Writes the non-clinical and clinical overviews. After the course, they lay out toxicology and comparability data the way a reviewer and a due diligence team actually read it.

  • Biologics Project Manager

    Owns the submission date. After the course, they run a pre-submission checklist that finds the missing validation report while there is still time to get it.

Roles: Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Sort a biologic into the centralized procedure and name the European Medicines Agency guidelines that apply to it.
  2. Arrange Modules 1 to 5 of a Common Technical Document so it passes validation without layout queries.
  3. Write an active substance section that carries the full process description and the stability evidence.
  4. Set release specifications and methods for the finished product that match what Module 3 states.
  5. Draft the Module 2.4 and 2.5 overviews, including bridging data against a non-European reference product.
  6. Classify a post-approval change as Type IA, Type IB, Type II or extension and update the pharmacovigilance system master file.
  7. Run a pre-submission checklist that finds missing validation reports and mismatches between summaries and study reports.

What the company gets

  • Your dossier reaches the European Medicines Agency with the Module 3 gaps already closed, so validation does not delay the start of your clock.
  • Buyers get a Common Technical Document that answers their due diligence questions without a follow-up call.
  • Your quality team holds release methods and limits that match the filed specification, which keeps batches moving.
  • The biosimilar file shows its comparability case in the right place, so reviewers have fewer reasons to ask for a redesign.
  • You hold a certificate per learner and a training record per person to show an inspector who was trained.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 8 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 20 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard3 h 20 min25 min a module, for regulatory, quality and business-development staff
Expanded6 h 40 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Regulatory affairsStandard3 h 20 min
Quality assurance and Qualified PersonStandard3 h 20 min

Course outline: 8 modules

8 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Pick the European Medicines Agency rules that apply to your biologic

    • Why Regulation 726/2004 sends your biologic down the centralized route, not a national one.
    • How to find the guidelines that apply to your product class in one sitting, not a long search.
    • What the Rapporteur and Co-Rapporteur look for first, so their list of questions comes back short.
  2. 2Build a Common Technical Document that passes validation

    • What to do when validation flags your Module 3 layout before the application is even accepted.
    • The Modules 1 to 5 folder structure that lets a reviewer find every document on the first try.
    • How to order your summaries so a buyer reaches the efficacy data without asking where it is.
  3. 3Draft the Module 3 active substance section reviewers can check

    • Why one missing critical quality attribute in the control strategy turns into a major objection.
    • How to describe the manufacturing process so the inspector has no reason to phone you.
    • The stability evidence that backs the active substance shelf life you request.
  4. 4Set finished product controls that hold up at batch release

    • What to do when a batch release result drifts from the specification filed in Module 3.
    • How to write release methods for the drug product that a European auditor accepts without comment.
    • The finished product controls a buyer looks for before they sign, and where to show them.
  5. 5Write non-clinical and clinical overviews buyers accept

    • Why missing bridging data against a non-European reference product brings objections to a biosimilar.
    • How to lay out the Module 2.4 non-clinical overview so the safety case is visible at first read.
    • The parts of the Module 2.5 clinical overview a partner reads first during due diligence.
  6. 6Design biosimilar comparability studies that avoid redo loops

    • How to match your comparative quality studies to the current European biosimilar guidelines.
    • What to do when your clinical comparability design risks rejection before the first patient is dosed.
    • The statistical approaches that make the case for biosimilarity before anyone asks for another trial.
  7. 7Submit the electronic dossier and classify each variation

    • How to build the electronic Common Technical Document so the upload goes through on the first attempt.
    • When a post-approval change is Type IA, Type IB or Type II, and when it needs an extension.
    • The pharmacovigilance system master file updates that keep your marketing authorization in order.
  8. 8Catch missing documents before the pre-submission review

    • How one missing validation report starts your authorization clock late, and how to spot it first.
    • The pre-submission checklist that finds the gap before the European Medicines Agency does.
    • Why a mismatch between the clinical summary and the study report draws questions, and how to catch it.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

8 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 20 min in the briefing length and 6 h 40 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 72 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team